ReviewMolecular and cellular pediatrics2023
Metamizole-induced agranulocytosis (MIA): a mini review.
Review in Molecular and cellular pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- A systematic review and pharmacovigilance analysis of the risk of agranulocytosis associated with metamizole use.Scientific reports · 2025Pooled it
- Adverse effects of dipyrone (Metamizole) use during pregnancy on offspring health: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Molecular Mechanisms of Acute Drug Toxicity in Polypharmacy: Analgesic-Psychotropic Interactions.International journal of molecular sciences · 2026Review
- Cystitis in guinea pigs (Cavia porcellus): Clinical findings and treatment outcomes.The Veterinary record · 2026Article
- Cross-Reactivity and Cross-Intolerance Among Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Clinical Patterns, COX-1-Mediated Mechanisms, and Implications for COX-2 Inhibitors and Paracetamol.International journal of molecular sciences · 2026Review
- Factors Influencing the Use of G-CSF in Drug-Induced Agranulocytosis.Hematology reports · 2026Review
- Dipyrone use in Brazil: clinical conditions, sociodemographic characteristics, population attitudes and perceptions.Cadernos de saude publica · 2026Article
- Metamizole-induced agranulocytosis from a German intensive care perspective.Frontiers in medicine · 2026Article
- The effect of scheduled metamizole on opioid consumption after cardiac surgery.Frontiers in pharmacology · 2026Article
- Performance of DeepSeek-R1, ChatGPT (GPT-o3-mini), and Gemini 2.0 Flash on German Medical Multiple-Choice Questions: Comparative Evaluation.JMIR formative research · 2025Article
- Learning From the Uncommon in Common Practice: A Case Report on Metamizole-Induced Agranulocytosis.Cureus · 2025Article
- Impact of lymphocyte transformation test on the diagnostic accuracy of the culprit drug in drug-induced cytopenias: a case-control study.Frontiers in pharmacology · 2025Article
- A probable case of metamizole-induced neutropaenia presenting 10 days after drug discontinuation.SAGE open medical case reports · 2025Article
- Metamizole in the Management of Musculoskeletal Disorders: Current Concept Review.Journal of clinical medicine · 2024Review
- 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats.Journal of feline medicine and surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metamizole is an analgesic, antipyretic, and spasmolytic drug in Germany only approved for the treatment of severe pain or high fever that does not respond to other measures. In recent years, an increased use has been described among both adults and children, often against the approved indication. The most important side effect of metamizole is the development of agranulocytosis (neutrophil count < 500/µL). Incidence of metamizole-induced agranulocytosis (MIA) ranges depending on the study from 0.96 cases per million per year to 1:1602 per patient and metamizole prescription. The risk of agranulocytosis in children remains unclear, but is probably lower than in adults. Female gender and older age are associated with higher incidence, reflecting prescription distribution. MIA is dose-independent and risk seems to increase with duration of intake. In patients with past exposure, re-exposure may lead to rapid onset. MIA is believed to be induced either through immunologic or toxic mechanisms. MIA presents with fever, sore throat, fatigue, and mucosal inflammation, up to ulceration. Even in the case of suspected MIA, treatment with metamizole should be immediately paused and an examination of the blood cell count is required. In case of local or systemic infections, empirical therapy with broad-spectrum antibiotics should be administered. G-CSF therapy should be limited to patients with poor prognostic factors. The patient should be monitored closely until the neutrophil count returns to normal. Re-exposure to metamizole must be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.